Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indication-Based Pricing Hurdle A Block For Roche's Ocrevus In UK

Executive Summary

The UK's National Institute for Health and Care Excellence rejected Roche's ocrelizumab for provision to adults with primary progressive multiple sclerosis due to cost grounds and efficacy uncertainties - but observers expect a compromise to be eventually struck.

You may also be interested in...



MediciNova's Ibudilast Shows Potential In Progressive MS

The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.

Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus

After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.

AstraZeneca Links With Accent To Target RNA-Modifying Proteins

AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Related Companies

UsernamePublicRestriction

Register

CO167768

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel